PRO: Patients With Advanced Cirrhosis and Portal Vein Thrombosis Should Receive Anticoagulation
Uyen Kim To, Guadalupe Garcia‐Tsao – 2 October 2018
Paracentesis Model for Junior Doctors
Jemma Mildon, Johann Willers, Sam J. Thomson – 2 October 2018
CON: Anticoagulation for Portal Vein Thrombosis in Advanced Cirrhosis
Kevin M. Rank, John Lake – 2 October 2018
PRO: Patients With Advanced Cirrhosis and Portal Vein Thrombosis Should Receive Anticoagulation
Uyen Kim To, Guadalupe Garcia‐Tsao – 2 October 2018
Risk of Nonsteroidal Anti‐inflammatory Drugs and Safety of Acetaminophen in Patients with Advanced Liver Disease
Miguel H. Malespin – 2 October 2018
Down‐regulation of TROP‐2 Predicts Poor Prognosis of Hepatocellular Carcinoma Patients
Sarah T. K. Sin, Yan Li, Ming Liu, Yun‐Fei Yuan, Stephanie Ma, Xin‐Yuan Guan – 2 October 2018 – Hepatocellular carcinoma (HCC) is one of the most common and lethal cancer types worldwide, especially in Asian countries. Genetic alterations, including hyperactivation of oncogenes and loss of expression of tumor suppressor genes, greatly contribute to the initiation and progression of HCC. Here we report that down‐regulation of trophoblast cell surface antigen 2 (TROP‐2) was frequently detected in HCC.
CON: Anticoagulation for Portal Vein Thrombosis in Advanced Cirrhosis
Kevin M. Rank, John Lake – 2 October 2018
Primer on Percutaneous Ablation of Benign Liver Tumors
Shane A. Wells, Timothy J. Ziemlewicz, Meghan G. Lubner – 2 October 2018
Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
Shogo Takahashi, Naoki Tanaka, Tatsuki Fukami, Cen Xie, Tomoki Yagai, Donghwan Kim, Thomas J. Velenosi, Tingting Yan, Kristopher W. Krausz, Moshe Levi, Frank J. Gonzalez – 1 October 2018 – Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide, and an association between altered bile acid (BA) metabolism, down‐regulation of farnesoid X receptor (FXR), which is a master regulator of BA metabolism, and hepatocarcinogenesis has been documented.